Novavax NanoFlu and COVID-Influenza Combination Vaccine Development 2022

Loading viewer...

investor_presentation

Format: PDF investor_presentation

Novavax presents development updates on its investigational NanoFlu vaccine and COVID-19-influenza combination vaccine candidates. The presentation covers clinical trial timelines, regulatory pathways, and the company's vaccine development programs including NVX-CoV2373 and Omicron-specific vaccine efforts.

Browse all investor_presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Novavax

View all →

Novavax Corporate Overview & Investor Deck May 2021

investor_presentation

42 Pages

Novavax Investor Presentation 2016 - Pipeline & Clinical Trials

investor_presentation

Similar investor_presentations from other companies

Browse all →

Sachem Capital Corp. SACH May 2024 Investor Presentation

investor_presentation

24 Pages

Sachem Capital Corp.

Woodside Energy 2023 AGM Investor Briefing

investor_presentation